TP53突变预测骨髓增生异常综合征患者对地西他滨诱导的完全缓解
本研究在109例初诊骨髓增生异常综合征(MDS)患者中检测28个目标基因的基线突变,发现TP53突变可预测地西他滨(DAC)诱导的完全缓解(CR),15例TP53突变患者中10例(66.7%)达到CR;单因素和多因素分析显示TP53突变是唯一预测CR的分子标志,但TP53突变与生存改善无关,不良结局归因于CR后早期复发和向急性髓系白血病转化。
要点
- 109例MDS患者中,15例携带TP53突变,其中10例(66.7%)达到完全缓解。
- 单因素和多因素分析显示TP53突变是唯一预测DAC诱导CR的分子标志。
- TP53突变与更高CR率相关,但与生存改善无关,不良结局源于CR后早期复发和白血病转化。
核心结论
- TP53突变可能预测MDS患者对地西他滨诱导的完全缓解。
- DAC诱导的缓解可能源于对携带突变TP53基因的恶性克隆的部分抑制。
研究设计与样本
- 研究纳入109例初诊骨髓增生异常综合征患者,检测28个目标基因的基线突变,分析其与地西他滨(DAC)疗效的关系。
主要发现
- 15例携带TP53突变的患者中,10例(66.7%)达到完全缓解(CR)。
- 单因素和多因素分析显示,TP53突变是唯一预测MDS患者对DAC达到CR的分子标志。
- 10例TP53突变且达到CR的患者中,9例因5号和/或7号染色体异常而呈现复杂核型,8例存在单体。
- TP53突变与更高的CR频率相关,但与生存改善无关。
- 不良结局归因于CR后早期复发和向急性髓系白血病转化。
关键数值与推荐
- TP53突变患者中CR率为66.7%(10/15)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To identify the molecular signatures that predict responses to decitabine (DAC), we examined baseline gene mutations (28 target genes) in 109 myelodysplastic syndrome (MDS) patients at diagnosis. We determined that TP53 mutations predicted complete response (CR), as 10 of 15 patients (66·7%) who possessed TP53 mutations achieved a CR. Univariate and multivariate analyses showed that TP53 mutations are the only molecular signatures predictive of a CR to DAC in MDS. Among the ten patients with TP53 mutations who achieved a CR, nine presented with complex karyotypes due to abnormalities involving chromosome 5 and/or chromosome 7, and eight possessed monosomies. Although TP53 mutations were associated with a higher frequency of CRs, they were not associated with improved survival. Poor outcomes were attributed to early relapses and transformation to acute myeloid leukaemia after CR. Post-DAC therapy patient gene mutation profiles showed that most CR patients exhibited fewer gene mutations after achieving a CR. It seems that suppression of these gene mutations was facilitated by DAC, resulting in a CR. In summary, TP53 mutations might predict decitabine-induced complete responses in patients with MDS. DAC-induced responses may result from partial suppression of malignant clones containing mutated TP53 genes.
引用
- Chang CK, Zhao YS, Xu F, et al. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. Br J Haematol. 2016. PMID: 27984642. doi:10.1111/bjh.14455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。